Products
IFU
LEPU Medical
LEPU Medical
MWN117 Injection

MWN117 Injection

Investigational GalNAc-siRNA targeting INHBE.
MWN117 Injection
MWN117 Injection
Enquire Now

Clinical Trials


1793674880160755.jpg

View on ClinicalTrials.gov



Development Highlights


1. Targeting Liver–Adipose Signaling

An investigational siRNA designed to silence hepatic INHBE expression and reduce Activin E production, modulating liver–adipose signaling to explore a non-incretin approach to obesity treatment.

2. Potential to Improve Body Composition
Supported by human genetic evidence and preclinical findings, MWN117 is being investigated for its potential to reduce visceral fat and improve body composition.

3. Potential Beyond Obesity: Relevance to MASH
By targeting liver–adipose signaling, MWN117 may offer opportunities for future investigation in metabolic dysfunction–associated steatohepatitis (MASH), with a focus on hepatic fat accumulation and related metabolic dysfunction.


For licensing and partnership inquiries, please contact us (bd@lepu-medical.com).


Thank You for Your Attention on Lepu Medical!

Email us with any questions or inquiries or use our contact data. We would be happy to answer your questions.

Submit
Submit